X0609 4 2026-09-15 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001228684 LINK WILLIAM J PHD false C/O TARSUS PHARMACEUTICALS, INC. 17700 LAGUNA CANYON ROAD, FLOOR 4 IRVINE CA 92618 1 0 0 0 1 Common Stock 2026-09-15 4 M 0 201 A 106987 D Common Stock 2026-09-15 4 S 0 11675 78.33 D 95312 D Common Stock 2026-09-15 4 S 0 759 79 D 94553 D Common Stock 2026-09-15 4 S 0 66 80.01 D 94487 D Restricted Stock Units 2026-09-15 4 M 0 201 0 D Common Stock 201 605 D The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each RSU represents a contingent right to receive one share of the Company's common stock. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. /s/ Scott Sieckert, Attorney-in-Fact 2026-09-17